Meeting
2019 Genitourinary Cancers Symposium
Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.
Authors
Xiting Cao
Novartis Pharmaceutical Corp, East Hanover, NJ
Xiting Cao , Derek Tang , Barbara Elizabeth Ratto , Austin Poole , Shoba Ravichandran , Lixian Jin , Wei Gao , Elyse Swallow , Nicholas J. Vogelzang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 573)
DOI
10.1200/JCO.2019.37.7_suppl.573
Abstract #
573
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).
First Author: Sonam Ansel
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin